Advanced Breast Cancer Guidelines in Latin America : Assessment, Adaptation, and Implementation of Fifth Advanced Breast Cancer Consensus Guidelines
PURPOSE: As the fifth international consensus on advanced breast cancer (ABC5) established guidelines for the management of this disease, the aim of this article was to present the applicability of the consensus recommendations and to generate knowledge to improve access.
METHODS: Sixty-one recommendation statements were selected and discussed by 15 breast cancer experts from Latin America (LA). After the discussion, the level of consensus was determined through a vote. In addition to this, the level of access to each of the recommendations presented, according to the country and health system, was exposed.
RESULTS: Latin American experts had a high level of agreement with the ABC5 consensus recommendations (range, 83%-100%). Twelve of 61 statements are not available for all patients in LA. Among the limitations to access, the following ones are described: limited access to certain technologies (stereotactic body radiotherapy, positron emission tomography-computed tomography), the high costs of drugs that limits access to treatment with CDK4/6 inhibitors, pertuzumab, or poly(ADP-ribose) polymerase inhibitors, and the lack of molecular tests for access to therapeutic targets, as well as the difficult geography and cultural diversity of our continent.
CONCLUSION: Despite the great relevance of the recommendations of the ABC5 consensus guidelines, we highlight that we still need to improve access for all patients, regardless of the country or health system they are in, for which we call to action to policy makers and patient groups to improve clinical outcomes of patients with advanced breast cancer in our region.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
JCO global oncology - 10(2024) vom: 01. Feb., Seite e2200067 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Valencia, Fernando [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 05.02.2024 Date Revised 10.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1200/GO.22.00067 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367905558 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367905558 | ||
| 003 | DE-627 | ||
| 005 | 20240210233213.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240202s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/GO.22.00067 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1287.xml |
| 035 | |a (DE-627)NLM367905558 | ||
| 035 | |a (NLM)38301184 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Valencia, Fernando |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Advanced Breast Cancer Guidelines in Latin America |b Assessment, Adaptation, and Implementation of Fifth Advanced Breast Cancer Consensus Guidelines |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.02.2024 | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a PURPOSE: As the fifth international consensus on advanced breast cancer (ABC5) established guidelines for the management of this disease, the aim of this article was to present the applicability of the consensus recommendations and to generate knowledge to improve access | ||
| 520 | |a METHODS: Sixty-one recommendation statements were selected and discussed by 15 breast cancer experts from Latin America (LA). After the discussion, the level of consensus was determined through a vote. In addition to this, the level of access to each of the recommendations presented, according to the country and health system, was exposed | ||
| 520 | |a RESULTS: Latin American experts had a high level of agreement with the ABC5 consensus recommendations (range, 83%-100%). Twelve of 61 statements are not available for all patients in LA. Among the limitations to access, the following ones are described: limited access to certain technologies (stereotactic body radiotherapy, positron emission tomography-computed tomography), the high costs of drugs that limits access to treatment with CDK4/6 inhibitors, pertuzumab, or poly(ADP-ribose) polymerase inhibitors, and the lack of molecular tests for access to therapeutic targets, as well as the difficult geography and cultural diversity of our continent | ||
| 520 | |a CONCLUSION: Despite the great relevance of the recommendations of the ABC5 consensus guidelines, we highlight that we still need to improve access for all patients, regardless of the country or health system they are in, for which we call to action to policy makers and patient groups to improve clinical outcomes of patients with advanced breast cancer in our region | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Gómez, Henry L |e verfasserin |4 aut | |
| 700 | 1 | |a Neciosup, Silvia P |e verfasserin |4 aut | |
| 700 | 1 | |a Limón, Ronald |e verfasserin |4 aut | |
| 700 | 1 | |a Torrico, María Del Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Morillas, Lena |e verfasserin |4 aut | |
| 700 | 1 | |a Torres, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez, Cesar |e verfasserin |4 aut | |
| 700 | 1 | |a Araya, Ingiborg |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez, Rodolfo |e verfasserin |4 aut | |
| 700 | 1 | |a Bruges, Ricardo |e verfasserin |4 aut | |
| 700 | 1 | |a Vargas, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Soria, Tannia |e verfasserin |4 aut | |
| 700 | 1 | |a Muñoz, René |e verfasserin |4 aut | |
| 700 | 1 | |a Riofrío, Mauricio |e verfasserin |4 aut | |
| 700 | 1 | |a Gálvez, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Ruiz, Rossana |e verfasserin |4 aut | |
| 700 | 1 | |a Benites, Pilar |e verfasserin |4 aut | |
| 700 | 1 | |a Cardoso, Fatima |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JCO global oncology |d 2020 |g 10(2024) vom: 01. Feb., Seite e2200067 |w (DE-627)NLM30617877X |x 2687-8941 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2024 |g day:01 |g month:02 |g pages:e2200067 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1200/GO.22.00067 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2024 |b 01 |c 02 |h e2200067 | ||